NS5806, widely used as a Kv4-selective activator, also activates TREK-1 and TREK-2 potassium channels.
This publication was awarded the '2024 Technology Innovation Publication Award' by the Safety Pharmacology Society.
1Amgen Research, Translational Safety and Bioanalytical Sciences, Amgen, Inc., Thousand Oaks, California, USA
2Metrion Biosciences Ltd, Granta Center, Cambridge, United Kingdom
3Hybrid Modality Engineering, Amgen, Inc., Thousand Oaks, California, USA
4Cardiometabolic Disorders, Amgen, Inc., Thousand Oaks, California, USA
Nucleic Acid Therapeutics, 2022
NS5806, widely used as a Kv4-selective activator, also activates TREK-1 and TREK-2 potassium channels.
Nature Communications paper ‘The nucleobase guanine at the 3′-terminus of oligonucleotide RGLS4326 drives off-target AMPAR inhibition and CNS toxicity'